© Reuters. Veru (VERU) Shares Up 35% Pre-market on Overwhelming COVID-19 Oral Drug Efficacy
Veru Inc. (NASDAQ:) shares are gaining over 30% in heavy pre-market buying and selling after the corporate introduced that its COVID-19 drug candidate lowered deaths by 55% in hospitalized COVID sufferers in Section 3 trial. Because of the “overwhelming” efficacy of the research, Impartial Information Security Monitoring Committee unanimously really helpful that the Section 3 research be halted, they usually additional remarked that no security issues have been recognized.
